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O ver thepast decade, newclinical definitions anddiagnos-tic criteria, facilitated by a specific biomarker, aquapo-rin-4 (AQP4)–reactive autoantibodies (AQP4-IgG), led to
the recognition that there is a broader clinical spectrum of syn-
dromes reasonably classified as being related to neuromyelitis op-
tica (NMO); these are now referred to asNMOspectrumdisorders.
Serum IgG1 antibodies against the water channel AQP4 are highly
specific for NMO spectrumdisorders, the clinical features of which
include inflammation of the optic nerve, spinal cord, and specific
brain areas, which frequently are sites of high AQP4 expression.1-5
Magnetic resonance imaging (MRI) represents themost important
nonserological paraclinical parameter to facilitate the diagnosis of
NMOspectrumdisorder.During theacutediseasephase,MRIof the
affected optic nerve and spinal cord may reveal swelling and con-
trastenhancementcausedbyblood-brainbarrierbreakdown.These
features are hypothesized to be triggered by damage to astrocytic
end-feet at the glia limitans of the blood-brain barrier.
The spinal cord lesions in patients with multiple sclerosis (MS)
usually span less than 1 vertebral segment and are commonly
peripherally located within the white matter (WM) of the cervical
spinal cord. By comparison, the spinal cord lesions in patients with
NMO spectrum disorder are typically centrally located in the cross
section, extend longitudinally over 3 or more contiguous vertebral
segments, and occasionally span most of the length of the spinal
cord.6 Cerebral lesions in patients with NMO spectrum disorder
detected by use of conventional MRI are most commonly clinically
silent and nonspecific in appearance; however, lesions of the dien-
cephalon, periaqueductal region, and brainstem are more specific
for NMO. The clinical features of hypersomnolence, anorexia, amen-
orrhea, or intractable hiccups prompt consideration of NMO. Hence,
amore comprehensive description of brain parenchymal abnormali-
ties is needed for NMO spectrum disorder and may provide
enhanced metrics for distinguishing NMO spectrum disorder from
otherWMdisorders.
Multiple studies7-15 have focused on spinal cord and brain MRI
findings regarding NMO spectrum disorders using conventional
MRI techniques. During the last decade, several groups have
evaluated the use of nonconventional brain and spinal cord MRI
techniques, including ultrahigh-field strength MRI, proton MR
spectroscopy (1H-MRS), diffusion and diffusion tensor imaging,
magnetization transfer imaging (MTI), and functional MRI
(fMRI).16,17 Although all of these techniques are currently applied in
neurological diseases such asMS, they are still exclusive to research
and not widely used in daily clinical practice. Nevertheless, these
advancedMRI techniques may help distinguish NMO spectrum dis-
orders from MS and elucidate the pathophysiology of NMO spec-
Brain parenchymal lesions are frequently observed on conventional magnetic resonance
imaging (MRI) scans of patients with neuromyelitis optica (NMO) spectrum disorder, but the
specific morphological and temporal patterns distinguishing them unequivocally from lesions
caused by other disorders have not been identified. This literature review summarizes the
literature on advanced quantitative imagingmeasures reported for patients with NMO
spectrum disorder, including protonMR spectroscopy, diffusion tensor imaging,
magnetization transfer imaging, quantitative MR volumetry, and ultrahigh-field strengthMRI.
It was undertaken to consider the advancedMRI techniques used for patients with NMO by
different specialists in the field. Although quantitative measures such as protonMR
spectroscopy or magnetization transfer imaging have not reproducibly revealed diffuse brain
injury, preliminary data from diffusion-weighted imaging and brain tissue volumetry indicate
greater white matter than gray matter degradation. These findings could be confirmed by
ultrahigh-field MRI. The use of nonconventional MRI techniques may further our
understanding of the pathogenic processes in NMO spectrum disorders andmay help us
identify the distinct radiographic features corresponding to specific phenotypic
manifestations of this disease.
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trum disorders. Herein, we review the current status of advanced
MRI techniques for patients with NMO spectrum disorder.
Exploration of Normal-AppearingWM
and Normal-Appearing Gray Matter
ProtonMR Spectroscopy
Metabolic parameters quantified by use of 1H-MRS (eg, ratios of
N-acetylaspartate to creatine and choline to creatine, and absolute
concentrations of the metabolites) have been reported to be unal-
tered in the normal-appearing cerebral WM and normal-appearing
cerebral gray matter (GM) of patients with NMO spectrum disor-
der compared with patients with MS.18-20 However, a recent case
study of NMO spectrum disorders by Ciccarelli et al21 demon-
strated lower myo-inositol levels normalized to creatine levels in
the lesional cervical spinal cords of patients with NMO spectrum
disorder in comparison with patients with MS and matched
healthy controls. Myo-inositol is a molecule located in astrocytes;
low levels of myo-inositol estimated by use of 1H-MRS are there-
fore believed to indicate astrocytic damage.21 Ciccarelli et al21
hypothesize that this lesional pathology is distinctive among
patients with MS. Nevertheless, this finding needs confirmation by
a larger study and preferably also additional data on brain lesions.
So far, there is insufficient evidence that 1H-MRS is specifically sen-
sitive to NMO spectrum disorder–related brain parenchymal
alterations and may thus facilitate the distinction of these altera-
tions fromMS.
Diffusion Tensor Imaging
Diffusion tensor imaging indirectly characterizes the tissue’s integ-
rity and structure in vivo by probing the microscopic diffusion of
water molecules in the tissue (Figure 1).22 The 2 most commonly
quoted coefficients are the mean diffusivity and the fractional
anisotropy. The mean diffusivity measures the average diffusivity
of water molecules. It is therefore affected by the cell size and tis-
sue integrity. Fractional anisotropy measures the degree of direc-
tional anisotropy of the diffusion process and is useful for assessing
the structural integrity of WM and the degree of structural align-
ment within fiber tracts. Studies of animal models have shown that
2 other coefficients, parallel diffusivity and perpendicular diffusiv-
ity, provide additional information on WM structures that is more
specific to underlying histological processes than fractional anisot-
ropy or mean diffusivity.23 Parallel diffusivity may reflect diffusiv-
ity along the axon (ie, axonal integrity), whereas perpendicular dif-
fusivity represents diffusivity perpendicular to the axon (ie,
myelination).
In the brain and spinal cord tissues of patients with NMO spec-
trum disorder, both a decrease24 and an increase inmean diffusivity
and perpendicular diffusivity have been reported in different stud-
ies. Furthermore, a heightened variance of parallel diffusivity and a
decrease in fractional anisotropy were stated in a comparison with
healthy controls,25,26 potentially reflecting both axonal and myelin
damage.24,25,27-31 The normal-appearing WM abnormalities
described thus far seem to predominate in optic radiations and cor-
ticospinal tracts (spinal cord and posterior limb of the internal
capsule),27 although more widespread normal-appearing WM
abnormalities in the brain and spinal cord were also detected by use
of diffusion tensor imaging.25,26,28 Confirmation from larger studies
will be necessary. Normal-appearing GM abnormalities have been
observed in the thalamus and putamen.31 Normal-appearing WM
and GM abnormalities may be the consequence of both Wallerian
degeneration and focal demyelination in the brain. With regard to
spinal cord lesions, higher radial diffusivity within spinal cord tracts
was present in patients with NMO spectrum disorder compared
with patients with MS, which is consistent with the more pro-
nounced tissue destruction observed in patients with NMO spec-
trum disorder.24 An association betweenWMdiffusion changes and
clinical parameters (the Expanded Disability Status Scale and dis-
ease duration) has been reported for patients with NMO spectrum
disorder.25,32
In summary, radiological and pathological correlation studies
are needed to clarify the precise relationship between the altera-
tions within diffusion tensor imaging–derived measures and the
underlying histopathological processes. Although not yet estab-
lished in routine clinical application, diffusion tensor imaging may
have the potential to serve as an imaging surrogate marker in
emerging NMO clinical trials (as a secondary or exploratory end
point).
Magnetization Transfer Imaging
Magnetization transfer imaging applies an additional off-
resonance pulse to saturate protons associated with macromol-
ecules. Saturated protons may enter the pool of free (water) pro-
tons and transfer their magnetization, causing a signal decrease in
macromolecule-rich areas such as the brain parenchyma. By com-
parison, thesignalofmore fluidcomponents ispreserved.Thus,MTI
may reveal tissue damage due to demyelination.
Twoof3 small studiesusingMTI toevaluatepatientswithNMO
spectrum disorder have observed no differences between af-
fected individuals and healthy controls.17,33 However, Rocca et al34
Figure 1. Diffusion Tensor Imaging
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A, Fiber bundles are composed of axons with myelinated sheaths. B, The
corresponding diffusion tensor is modeled by an ellipsoid. Parallel diffusivity
(Dpar) corresponds to the diffusivity in themain direction of the fiber bundle
(reflecting axonal integrity), and perpendicular diffusivity (Dper) is related to the
diffusivity orthogonal to this direction (reflecting themyelination).
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found lower magnetization transfer ratio histogram–derived met-
rics forpatientswithNMOcomparedwithhealthy controls, and the
changeswereexclusive tonormal-appearingGMandcorrelatedwith
increased mean diffusivity. Unfortunately, this study34 was con-
ducted prior to the availability of AQP4 antibody testing. Conse-
quently, diagnosticmisclassificationmayhavebiased the results. In
summary, owing to the very limitednumberof studies andpatients
included, a conclusive answer to the value of MTI for patients with
NMOspectrumdisorder remainsopenand requires largerprospec-
tive studies.
Volumetric Evaluation
For patients with MS, MRI-detected abnormalities are typically
accompanied by decreased brain volume of the WM and GM.35
This atrophy correlates with the level of physical disability and
cognitive impairment.35 Several studies36-39 have investigated
changes in the WM and/or GM volume in patients with NMO.
Analyses of global volumetric atrophy demonstrated a markedly
decreased WM volume in patients with NMO spectrum disorder
compared with healthy participants.36,37 Blanc et al36 demon-
strated correlations between WM focal atrophy and cognitive
impairment in 28 patients with NMO. Focal WM atrophy included
the optic chiasm, pons, cerebellum, corpus callosum, and parts of
the frontal, temporal and parietal lobes, including the superior lon-
gitudinal fasciculus.
Inanother study,38 theExpandedDisabilityStatusScaleanddis-
ease duration were not significantly correlated with brain volume
for30patientswithNMO.AlthoughglobalGMatrophyhasnotbeen
described for patientswithNMOspectrumdisorder, focal thalamic
andprefrontalGMatrophywas identified in this small study38ofpa-
tients with NMO, although it was less severe than in patients with
MS.37,39 Moreover, the anatomical regional distribution of the de-
scribed focal GM and/or WM atrophy seems to differ between pa-
tientswithNMOspectrumdisorderandpatientswithMS.39This find-
ing is consistent with the study by Saji et al,40 who showed that
cognitive decline candevelopearly in patientswithNMOspectrum
disorder.
In aggregate, the data suggest the presence of diffuse WM
and focal GM atrophy in patients with NMO spectrum disorder,
even in those patients without cerebral T2-weighted hyperintense
lesions. Although technically feasible, atrophy measurements
have not become part of the clinical practice for patients with MS
or NMO. As with MS, for which numerous clinical trials with new
therapeutic compounds have applied atrophy measurements
mostly as secondary or exploratory end points, the effect of new
NMO therapies on brain atrophy could be assessed in upcoming
clinical trials.
Functional MRI
Functional MRI is a neuroimaging procedure that measures neural
activity based on changes in deoxyhemoglobin levels (blood oxy-
gen level–dependent [BOLD] signal). Two general approaches are
used: (1) activation fMRI, which measures the deoxyhemoglobin
signal modification during specified tasks, and (2) resting-state
fMRI, which correlates the synchrony of low-frequency fluctua-
tions of the BOLD signal in various regions while the brain is at rest
(Figure 2). The latter technique can be used to determine the
functional connectivity of neural networks.41 While both fMRI
techniques have been applied to patients with MS,42,43 there has
been only one study44 to date on the use of activation fMRI for
patients with NMO spectrum disorder. The study44 showed an
abnormal pattern of movement-associated cortical activation in
patients with NMO spectrum disorder (similar to that in patients
with MS) that extended beyond the “classical” sensorimotor net-
work and involved visual areas devoted to motion processing. The
correlation between fMRI changes and the extent of spinal cord
damage suggests that such functional cortical changes might play
an adaptive role in limiting the clinical outcome of the pathology of
NMO spectrum disorder.43
In patients with NMO spectrum disorder, the regions of func-
tional impairment and adaptation have been described by
resting-state fMRI studies despite the otherwise preserved global
brain integrity.42,44 Liu et al42 showed that patients with NMO
spectrum disorder had a reduced amplitude of low-frequency
Figure 2. Resting-State Functional Magnetic Resonance Imaging
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Axial and sagittal views of the brain funtional networkA
Expanded disability status scaleB
A, Axial (left) and sagittal (right) views of the brain functional network. Nodes
are located toward the coordinates of the regional centroids of the automated
anatomical labeling template. Short-distance connections corresponding to the
red edges are predominantly in the posterior cortex, whereas the long-distance
connections shown in blue are between the frontal cortex and the regions of
the parietal and temporal association cortex. B, Expanded Disability Status
Scale (EDSS) as a function of the hub disruption index. A hub disruption index of
0 corresponds to a normal network. The farther the index deviates from 0, the
more significant the reorganization of the network (in terms of topology). A
correlation score highlights the fact that the reorganization of the brain network
is a marker of the severity of the disease. The solid line represents the linear
regression fit across all participants.
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fluctuation in the precuneus, posterior cingulate cortex, and lin-
gual gyrus and increased amplitude of low-frequency fluctuation
in the middle frontal gyrus, caudate nucleus, and thalamus com-
pared with normal controls. Moreover, a moderate negative cor-
relation was observed between the Expanded Disability Status
Scale and the amplitude of low-frequency fluctuation in the left
middle frontal gyrus.42
From resting-state fMRI data, it is possible to model large-
scale human brain networks of regional cortical and subcortical
nodes with models such as the graph theory.45 Hemmert et al46
hypothesized that global network properties were conserved in
patients with NMO but that regional networks were reorganized.
This reorganization could be a marker of disease severity because
the authors found a reasonable correlation between disability and
the hub disruption index.46 These results indicate that functional
connectivity is modified in patients with NMO spectrum disorder
and that resting-state graph analysis may highlight brain plasticity
associated with network reorganization. Besides fair evidence of
alterations in brain functional networks, further longitudinal stud-
ies are needed to determine the role of fMRI in NMO spectrum
disorders.
Ultrahigh-Field and High-Field MRI
Striking advances in in vivobrain lesion imaginghavebeenmadeby
the application of ultrahigh-field strength MRI. The use of 7-T MRI
enables an unprecedented view of brain structures and pathology
onasubmillimeter scaleowing toahighsignal tonoise ratio.46White
matter lesionsarepresent innearly70%ofpatientswithNMOspec-
trum disorder who have a longstanding disease. The pattern of le-
sion distributionmay conform to brain regions known to have high
AQP4 expression, but inmany patients, the lesion pattern remains
nonspecific.47 In MS, no target antigen has been identified, so the
distribution of the lesions relative to the target antigen cannot be
addressed.Brain lesions inpatientswithMSarecharacteristically lo-
cated in perivenular regions, whereas this is not the case in pa-
tientswithNMOspectrumdisorder (Figure3); thisobservationmay
be helpful in differentiating NMO- fromMS brain lesions.48,49
In one 7-T MRI study of NMO spectrum disorders,50 the veins
coursing through the lesions were rare, and the central intra-
lesional veins were absent (with only few exceptions). Further-
more, a hypointense rim surroundingWM lesions, hypothesized to
represent iron-loadedmacrophages and activatedmicroglia, was a
commonfinding inpatientswithMS,but itwasnotdetectable inpa-
tientswithNMOspectrumdisorder (Figure4).47 Themajority of le-
sions (>85%) in patients with NMO spectrum disorder were
subcortical,46 and no periventricular lesions or “Dawson’s fingers,”
acharacteristic featureofMS,51wereobserved.52 Interestingly,none
of these studies described the macroscopic cortical pathology of
NMOspectrumdisorders,53 despite thedescription ofmicroscopic
meningeal inflammation, cortical demyelination, andneuronal loss
in histological analyses.54,55
Noevidenceof a specific cortical pathologyorof a specificmor-
phologyordistributionofbrainparenchymal lesions couldbe found
usingultrahigh-fieldMRI.Nevertheless, thecharacterizationofnear-
microscopic lesions facilitates distinguishing NMO spectrumdisor-
ders fromMS.
Conclusions
In contrast to studies of MS using advancedMRI techniques, stud-
ies of NMO spectrum disorders are still scarce, with often a limited
number of patients included (Table 1). Moreover, previous cohorts
werehighlyheterogeneouswith respect to theproportionofAQP4
antibody–seropositive and –seronegative patients, which pre-
cludes definite conclusions on distinct imaging features in these 2
subgroups.Avariety of advancedMRImeasures arediscussedwith
regard to their capacity todetectnonovert tissuedamageand to fa-
cilitate thedistinctionofNMOspectrumdisorders fromMS(Table2).
Althoughquantitativemeasures suchas 1H-MRSorMTIhavenot re-
producibly revealeddiffusebrain injury,diffusion-weighted imaging
and brain tissue volumetry indicate more WM injury than GM in-
jury. These findings were confirmed by use of ultrahigh-field MRI.
Withhighly resolving7-TMRI, nonspecific cerebralWMlesionswere
detectable, but GM pathology was absent.
The discrepancy between themacroscopic GM findings on ul-
trahigh-fieldMRI scans and themicroscopic pathology found inpa-
tientswithNMOspectrumdisordersuggests thatsomefMRIchanges
may result from an occult microscopic brain pathology. The dis-
ease specificity of these changes, however, is not yet clear. Future
longitudinal studies using age-matched and disease-matched con-
trols are warranted to elucidate the specificity of the cerebral MRI
findings regarding NMO spectrum disorders. However, because
these types of studies have not yet been conducted, patients with
definiteor suspectedNMOshouldnotbe routinely subjected toad-
vanced imaging techniques outside observational studies; instead,
inunclear casesof centralnervoussystemdemyelination, testing for
Figure 3. Optic Radiations
Optic radiation tractography was performed using a diffusion tensor
imaging/magnetic resonance imaging (MRI) scan (Siemens Avanto 1.5-T MRI
scanner, with 30 directions). Two seed points (the brightly colored fiber
bundles) have been defined, the first one in the lateral geniculate body and the
second one in the white matter at the posterior part of the occipital horn of the
lateral ventricle. The fiber bundles are color coded according to their directions
of impulse transmission.
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Figure 4. Magnetic Resonance Imaging Scans of Neuromyelitis Optica (NMO) andMultiple Sclerosis (MS)
Lesions at 7 T
Patient with MSA Patient with NMO spectrum disorderB
Multiple sclerosis lesions are
characteristically centered on a small
vein in T2*-weighted sequences (blue
arrowheads pointing to lesion surface
and yellow arrowheads pointing to
central intralesional vein) (A), a
finding not present in 7-T magnetic
resonance imaging scans of patients
with NMO spectrum disorder who
have brain parenchymal lesions (blue
arrowheads) (B).
Table 1. Survey of NMOSD Studies That Used AdvancedMRI Techniquesa
Study, Year
Patients With NMSOD
Healthy Controls, No.Total No. No. Tested for AQP4-IgG
Pichiecchio et al,17 2012 8 6b 7
Aboul-Enein et al,18 2010 8 8 8
Bichuetti et al,19 2008 16 NA 16
de Seze et al,20 2010 24 17 12
Ciccarelli et l,21 2013 5 5 11
Klawiter et al,24 2012 10 7 10
Liu et al,25 2012 27 NA 27
Rueda Lopes et al,26 2012 17 NA 17
Jeantroux et al,27 2012 20 NA 25
Liu et al,28 2012 26 18c 26
Yu et al,29 2008 19 NA 19
Yu et al,30 2006 16 NA 16
Zhao et al,31 2012 24 NA 24
Qian et al,32 2011 10 NA 12
Filippi et al,33 1999 8 NA 9
Rocca et al,34 2004 10 NA 15
Blanc et al,36 2012 28 18 28
Chanson et al,37 2013 30 17 30
Duan et al,38 2013 20 NA 20
Duan et al,39 2012 26 NA 26
Saji et al,40 2013 14 14 37
Liu et al,42 2011 17 NA 17
Liang et al,45 2011 17 NA 17
Hemmert et al,46 2013 12 NA 20
Kister et al,47 2013 10 10 0
Sinnecker et al,48 2012 10 9 0
Matthews et al,52 2013 44 44 0
Abbreviations: AQP4, aquaporin 4;
MRI, magnetic resonance imaging;
NA, not available; NMOSD,
neuromyelitis optica spectrum
disorder.
a To our knowledge, no longitudinal
studies on the use of advancedMRI
techniques for patients with
NMSOD have been published.
b Four patients tested positive.
c Sixteen patients tested positive.
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AQP4antibodies inhighly sensitive andspecific assays andconven-
tional MR imaging of the brain and the entire spinal cord should be
initiated to help establish or rule out a diagnosis of NMO spectrum
disorder.56 Futureobservational trials should strive formorehomo-
geneous patient cohorts in order to investigate possible differ-
ences in imaging features between seropositive and seronegative
patients. Emerging interventional trials of NMO with strict inclu-
sion and exclusion criteria could provide an excellent opportunity
to enhance our understanding of the association between disease
pathology and advanced imaging findings.
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Table 2. Summary of a Variety of AdvancedMRIMeasures
Technique Exemplary Marker Interpretation
Use for Distinguishing
NMOSD From MS
Proton MR
spectroscopy
NAA, MI Marker molecules for neurons (NAA) or
astrocytes (MI) are often expressed as
ratios to creatine or choline.
Poor
Diffusion tensor
imaging
MD, FA Indirectly characterizes tissue integrity
and structure. Can be used to
reconstruct CNS fiber tracts.
Potentially relevant,
confirmation studies
needed
Magnetization transfer
imaging
Magnetization transfer
ratio
Applies additional off-resonance pulse
to saturate protons associated with
macromolecules. May reveal
demyelination and remyelination.
Poor
Brain volumetry Brain parenchymal
fraction
Brain volumetry is an established
marker for neurodegenerative
processes. Various techniques are
applied.
Potentially relevant,
confirmation studies
needed
Functional MRI BOLD signal Assesses focal brain activity by changes
in oxygen consumption and local blood
perfusion during tasks or at resting
state.
Poor
Ultrahigh-field MRI Morphological imaging Ultrahigh-field MRI enables
near-microscopic resolution in vivo, as
well as increased sensitivity to T2*
contrast.
Good, characteristics of
MS-specific lesion not
present in NMOSD
Abbreviations: BOLD, blood oxygen
level–dependent; CNS, central
nervous system; FA, fractional
anisotropy; MD, mean diffusivity;
MI,myo-inositol; MRI, magnetic
resonance imaging; MS, multiple
sclerosis; NAA,N-acetylaspartate;
NMOSD, neuromyelitis optica
spectrum disorder.
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